Inozyme Pharma Inc. (INZY) stock has tumbled to a 52-week low, reaching a price level of just $2.37. This latest dip reflects a significant downturn for the biopharmaceutical company, which has seen its stock price plummet by nearly 40% over the past year. With a market capitalization of $165 million, InvestingPro analysis suggests the stock is currently undervalued, while analyst price targets range from $12 to $43. The 1-year change data paints a stark picture of the challenges faced by Inozyme Pharma, as investors have witnessed a -39.95% decline in the value of their holdings. The company, which specializes in developing treatments for rare metabolic disorders, has been navigating a tough market environment, leading to this notable low in its stock price. Despite the challenges, InvestingPro data shows the company maintains a strong liquidity position with a current ratio of 7.68, though it's quickly burning through cash. Three analysts have recently revised their earnings estimates upward for the upcoming period.
In other recent news, Inozyme Pharma reported positive interim results from its ENERGY 1 trial and Expanded Access Program, evaluating the investigational drug INZ-701. The treatment led to significant improvements in survival rates, heart function, and reductions in arterial calcifications. The company also completed enrollment for its ENERGY 3 trial, expecting topline data in early 2026. Inozyme received regulatory guidance for its ASPIRE pivotal trial, planning to initiate the trial in early 2026.
Inozyme has seen several analyst upgrades, including Jefferies initiating a Buy rating and Piper Sandler increasing its target for Inozyme to $43 while maintaining an Overweight rating. H.C. Wainwright reiterated a Buy rating and a $14.00 price target for Inozyme's shares.
The company announced approximately $23.8 million remaining in its at-the-market equity offering program, facilitated by Jefferies LLC. Inozyme plans to initiate a registrational trial for INZ-701 in calciphylaxis patients in 2025, pending regulatory approval and funding. These are among the recent developments in Inozyme Pharma's ongoing efforts in the biopharmaceutical sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.